Immix Observes Complete Response in Late-Stage Canine Cancer Patient and Doses First Two Patients in Human Phase 1b/2a Study

LOS ANGELES, Aug. 6, 2018 /PRNewswire/ -- Immix Biopharma, Inc. announced today that it has observed the complete response of an advanced, spontaneous malignancy in a 10-year-old companion dog after the administration of a single cycle of Imx-110. The dog showed a complete resolution of all clinical signs of disease several days after dosing, with immediate improvement in appetite and energy levels. The patient experienced no decrease in white blood cells - a reaction typically seen with standard treatment doxorubicin - or any other adverse effects.  Less than a week after treatment, he returned to his usual activities, according to his owner.  While this observed response was impressive, the company cautions that it is still a sample size of 1 and more studies are needed on larger canine patient cohorts.

Immix also announced that the first two human patients have been dosed in a phase 1b/2a clinical trial studying Imx-110 in refractory, advanced solid tumors. Professor Paul de Souza, Foundation Chair of Medical Oncology at Western Sydney University School of Medicine and lead Principal Investigator in the Immix phase 1/2a study, said, "As of now, we have dosed a patient with stage IV adenocarcinoma of the esophagus and a patient with advanced pancreatic cancer. Neither have experienced a drug-related toxicity to date, and we are incredibly excited to continue to enroll patients into the next cohort of our phase 1b/2a study."

Dr. Ilya Rachman, Immix co-founder and CEO, added, "We are incredibly grateful to the patients participating in these studies. Currently, the biopharmaceutical industry is exploring multiple approaches to treating cancer that include new ways to kill tumors using antibody drug conjugates, modified immune cells and checkpoint inhibitors - but few are focused on inhibiting the nature of tumor evolvability and resistance mechanisms that plague every therapeutic class in cancer.  By focusing on and inhibiting tumor resistance pathways, we have the potential to enable patients to live the rest of their lives normally, while keeping their disease at bay indefinitely, using a non-toxic cocktail of therapies - much like HIV is treated today."

Immix is currently enrolling patients in a phase 1b/2a study. For more information, see: https://clinicaltrials.gov/ct2/show/NCT03382340. The company is also meeting with prospective business partners and investors to finance new clinical development goals. For inquiries, please contact the company via email at [email protected].

About IMX-110
Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-tyrosine kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties, allowing it to deliver even more payload to tumors or other cell populations of interest, if needed. Imx-110 showed preclinical efficacy in glioblastoma, multiple myeloma, triple-negative breast, colorectal, ovarian, and pancreatic tumor models -- with the mechanism of action being a 5x increase in cancer cell apoptosis compared to doxorubicin alone, and a wholesale shift in the tumor microenvironment post administration.

About the Company
Immix Biopharma, Inc. is a privately-held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The company was founded by Vladimir Torchilin, Ph.D., D.Sc., Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; physician-scientist and clinical researcher Ilya Rachman, MD, PhD, MBA; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney. Immix's founding investor is a family office focused on harnessing scientific advances in order to engineer transformative and effective cancer treatments. For more information visit www.immixbio.com.

Media Contact
Ryan Witt
+1 (888) 958-1084
[email protected]

SOURCE Immix Biopharma, Inc.

Related Links

http://www.immixbio.com